Elevation Oncology Investor Relations Material
Latest events
Study Update
Elevation Oncology
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Elevation Oncology Inc
Access all reports
Elevation Oncology, Inc. is a biotechnology company focused on the discovery and development of targeted cancer therapies. The company specializes in creating antibody-drug conjugates (ADCs) to treat patients with solid tumors that have significant unmet medical needs. Their lead candidate, EO-3021, targets the Claudin 18.2 protein, which is expressed in various cancers, including gastric and pancreatic cancers. Elevation Oncology aims to selectively deliver cytotoxic agents directly to cancer cells, thereby improving treatment efficacy while minimizing damage to healthy tissues. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Elevation Oncology Inc
Study Update
Elevation Oncology Inc
Study Update
Elevation Oncology Inc
Latest articles
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
ELEV
Country
🇺🇸 United States